 Steven Johnson
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 15 | 2021 | 2469 | 1.560 |
Why?
| | Q Fever | 1 | 2019 | 5 | 0.680 |
Why?
| | Anti-Retroviral Agents | 3 | 2016 | 207 | 0.670 |
Why?
| | Endocarditis, Bacterial | 1 | 2019 | 36 | 0.660 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 106 | 0.620 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2019 | 256 | 0.600 |
Why?
| | 6-Phytase | 3 | 2012 | 3 | 0.530 |
Why?
| | Lilium | 3 | 2012 | 3 | 0.530 |
Why?
| | Drug Monitoring | 2 | 2016 | 184 | 0.520 |
Why?
| | Pichia | 2 | 2012 | 19 | 0.460 |
Why?
| | Kidney Transplantation | 1 | 2019 | 541 | 0.450 |
Why?
| | Vaccination | 1 | 2020 | 1204 | 0.410 |
Why?
| | Fasciola hepatica | 1 | 2012 | 4 | 0.400 |
Why?
| | Topography, Medical | 1 | 2012 | 12 | 0.400 |
Why?
| | Fascioliasis | 1 | 2012 | 6 | 0.400 |
Why?
| | Residence Characteristics | 1 | 2013 | 275 | 0.370 |
Why?
| | Lasers, Excimer | 1 | 2010 | 21 | 0.340 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2010 | 16 | 0.340 |
Why?
| | Myopia | 1 | 2010 | 36 | 0.330 |
Why?
| | Sexual Behavior | 1 | 2013 | 440 | 0.330 |
Why?
| | Intraoperative Complications | 1 | 2010 | 122 | 0.310 |
Why?
| | Surgical Flaps | 1 | 2010 | 121 | 0.310 |
Why?
| | Transplant Recipients | 2 | 2020 | 140 | 0.300 |
Why?
| | Antiviral Agents | 3 | 2020 | 645 | 0.280 |
Why?
| | Middle Aged | 13 | 2021 | 26737 | 0.230 |
Why?
| | Prisons | 2 | 2020 | 72 | 0.200 |
Why?
| | Telemedicine | 2 | 2020 | 662 | 0.190 |
Why?
| | HIV-1 | 4 | 2021 | 768 | 0.190 |
Why?
| | Hepatitis A | 1 | 2020 | 26 | 0.180 |
Why?
| | Humans | 24 | 2021 | 114686 | 0.180 |
Why?
| | New York | 1 | 2020 | 106 | 0.180 |
Why?
| | Hepatitis B Vaccines | 1 | 2020 | 46 | 0.180 |
Why?
| | Meningococcal Vaccines | 1 | 2020 | 48 | 0.180 |
Why?
| | Patient Compliance | 3 | 2014 | 525 | 0.170 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.170 |
Why?
| | Advance Directives | 1 | 2021 | 69 | 0.170 |
Why?
| | Kidney | 2 | 2019 | 1188 | 0.170 |
Why?
| | Advisory Committees | 1 | 2020 | 208 | 0.160 |
Why?
| | Myocarditis | 1 | 2020 | 93 | 0.160 |
Why?
| | Pollen | 2 | 2010 | 24 | 0.160 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2019 | 217 | 0.150 |
Why?
| | Renal Insufficiency | 1 | 2020 | 137 | 0.150 |
Why?
| | RNA, Viral | 2 | 2020 | 565 | 0.150 |
Why?
| | Cytomegalovirus Infections | 1 | 2020 | 180 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2020 | 159 | 0.150 |
Why?
| | Papillomavirus Vaccines | 1 | 2020 | 223 | 0.150 |
Why?
| | Advance Care Planning | 1 | 2021 | 197 | 0.150 |
Why?
| | Time Factors | 4 | 2020 | 6115 | 0.140 |
Why?
| | Prisoners | 1 | 2019 | 124 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 250 | 0.140 |
Why?
| | Adult | 11 | 2021 | 30550 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2019 | 411 | 0.140 |
Why?
| | Antibodies, Viral | 1 | 2020 | 520 | 0.140 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 338 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 330 | 0.120 |
Why?
| | Female | 12 | 2021 | 59507 | 0.120 |
Why?
| | Viral Load | 2 | 2014 | 405 | 0.120 |
Why?
| | Decision Making | 1 | 2021 | 782 | 0.110 |
Why?
| | Male | 14 | 2021 | 55596 | 0.110 |
Why?
| | United States | 5 | 2020 | 12183 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 413 | 0.110 |
Why?
| | Comorbidity | 2 | 2019 | 1448 | 0.110 |
Why?
| | Phosphorous Acids | 1 | 2012 | 12 | 0.100 |
Why?
| | Phytic Acid | 2 | 2010 | 41 | 0.100 |
Why?
| | Refugees | 1 | 2013 | 54 | 0.100 |
Why?
| | Aged | 4 | 2021 | 19074 | 0.100 |
Why?
| | Mass Screening | 3 | 2020 | 1004 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1317 | 0.100 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 253 | 0.100 |
Why?
| | Life Cycle Stages | 1 | 2012 | 32 | 0.100 |
Why?
| | Africa | 1 | 2012 | 94 | 0.100 |
Why?
| | Aging | 1 | 2021 | 1618 | 0.100 |
Why?
| | Primary Health Care | 1 | 2021 | 1513 | 0.100 |
Why?
| | Cloning, Molecular | 1 | 2012 | 522 | 0.090 |
Why?
| | Travel | 1 | 2012 | 121 | 0.090 |
Why?
| | Adenine | 1 | 2012 | 219 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2021 | 12550 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1481 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2286 | 0.090 |
Why?
| | Pharmacy Service, Hospital | 1 | 2011 | 83 | 0.090 |
Why?
| | Botulinum Toxins, Type A | 1 | 2010 | 40 | 0.090 |
Why?
| | Colorado | 5 | 2020 | 4099 | 0.080 |
Why?
| | Genetic Vectors | 1 | 2010 | 289 | 0.080 |
Why?
| | Protein Folding | 1 | 2010 | 239 | 0.080 |
Why?
| | Drug Prescriptions | 1 | 2011 | 239 | 0.080 |
Why?
| | Anti-HIV Agents | 2 | 2012 | 666 | 0.080 |
Why?
| | Risk Factors | 3 | 2021 | 8632 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 616 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2010 | 296 | 0.070 |
Why?
| | Prospective Studies | 3 | 2019 | 6220 | 0.070 |
Why?
| | Age Factors | 1 | 2013 | 2894 | 0.070 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2006 | 54 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 3 | 2014 | 257 | 0.060 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2005 | 11 | 0.060 |
Why?
| | Substance-Related Disorders | 1 | 2013 | 947 | 0.060 |
Why?
| | Lamivudine | 1 | 2005 | 59 | 0.060 |
Why?
| | Delivery of Health Care | 3 | 2019 | 833 | 0.060 |
Why?
| | Salvage Therapy | 1 | 2005 | 127 | 0.060 |
Why?
| | Medication Adherence | 1 | 2009 | 536 | 0.060 |
Why?
| | Incidence | 1 | 2010 | 2313 | 0.050 |
Why?
| | Neurons | 1 | 2010 | 1280 | 0.050 |
Why?
| | Disease Progression | 1 | 2009 | 2380 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2020 | 19 | 0.040 |
Why?
| | Coinfection | 1 | 2021 | 120 | 0.040 |
Why?
| | Quarantine | 1 | 2020 | 24 | 0.040 |
Why?
| | Death | 1 | 2021 | 107 | 0.040 |
Why?
| | Drug Users | 1 | 2020 | 41 | 0.040 |
Why?
| | Animals | 4 | 2021 | 31706 | 0.040 |
Why?
| | Immunoassay | 1 | 2020 | 95 | 0.040 |
Why?
| | Proteinuria | 1 | 2020 | 77 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2010 | 1815 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 112 | 0.040 |
Why?
| | Young Adult | 2 | 2011 | 10469 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 923 | 0.040 |
Why?
| | Cause of Death | 1 | 2019 | 361 | 0.040 |
Why?
| | Risk-Taking | 1 | 2020 | 333 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 295 | 0.040 |
Why?
| | Base Sequence | 2 | 2012 | 2114 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1342 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2012 | 1982 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1373 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2012 | 2785 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1578 | 0.030 |
Why?
| | Prevalence | 1 | 2020 | 2251 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2020 | 763 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 22 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 771 | 0.030 |
Why?
| | Hospitalization | 1 | 2021 | 1752 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 797 | 0.020 |
Why?
| | Gene Dosage | 1 | 2012 | 129 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2012 | 323 | 0.020 |
Why?
| | Population Surveillance | 1 | 2014 | 392 | 0.020 |
Why?
| | Plasmids | 1 | 2012 | 343 | 0.020 |
Why?
| | Creatinine | 1 | 2012 | 425 | 0.020 |
Why?
| | Toes | 1 | 2010 | 26 | 0.020 |
Why?
| | Hospitals, University | 1 | 2011 | 172 | 0.020 |
Why?
| | Reflex | 1 | 2010 | 64 | 0.020 |
Why?
| | Neuromuscular Junction | 1 | 2010 | 53 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1078 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 337 | 0.020 |
Why?
| | Protein Engineering | 1 | 2010 | 98 | 0.020 |
Why?
| | Drug Carriers | 1 | 2010 | 112 | 0.020 |
Why?
| | Temperature | 1 | 2012 | 565 | 0.020 |
Why?
| | Informed Consent | 1 | 2010 | 161 | 0.020 |
Why?
| | Protein Transport | 1 | 2010 | 395 | 0.020 |
Why?
| | Public Health | 1 | 2013 | 433 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2012 | 1230 | 0.020 |
Why?
| | Motor Neurons | 1 | 2010 | 213 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 796 | 0.020 |
Why?
| | Urban Population | 1 | 2010 | 397 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1421 | 0.020 |
Why?
| | Escherichia coli | 1 | 2010 | 720 | 0.020 |
Why?
| | Histidine | 1 | 2006 | 57 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2006 | 152 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2011 | 635 | 0.020 |
Why?
| | Neoplasms | 1 | 2019 | 2097 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2006 | 353 | 0.020 |
Why?
| | Molecular Structure | 1 | 2006 | 434 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2006 | 993 | 0.010 |
Why?
| | Phylogeny | 1 | 2006 | 789 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 9088 | 0.010 |
Why?
| | Rats | 1 | 2006 | 4958 | 0.010 |
Why?
| | Mutation | 1 | 2005 | 3346 | 0.010 |
Why?
| | Mice | 1 | 2010 | 14869 | 0.010 |
Why?
| | Adolescent | 1 | 2011 | 17844 | 0.010 |
Why?
|
|
Johnson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|